# Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer

> **NCT03881683** · NA · COMPLETED · sponsor: **Institut de Cancérologie de Lorraine** · enrollment: 24 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DIAGNOSTIC_TEST:** HRD and BRCA mutations

## Key facts

- **NCT ID:** NCT03881683
- **Lead sponsor:** Institut de Cancérologie de Lorraine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-21
- **Primary completion:** 2021-02-19
- **Final completion:** 2021-02-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881683, "Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03881683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*